|
|
|
|
| It's no secret that on-going research aims to improve the efficacy and specificity of non-viral approaches for genetic engineering. But the field is rapidly evolving with research aimed at improving transfection efficiency, targeting, and safety profiles of non-viral delivery systems. Join Cell & Gene Live to discuss the most notable approaches and recent breakthroughs as well as promising non-viral vectors used in clinical trials. Attendance is free thanks to the support of MaxCyte. |
|
|
|
|
By Tyler Menichiello, contributing editor | Heidi Zhang, Ph.D., explains Tune Therapeutics' epigenetic approach to gene therapy and how the company is preparing its lead candidate for the clinic, as well as it's modular approach to automation. |
|
|
|
|
| Response To FDA Black Box Warning | White Paper | Theragent | The FDA has launched an investigation into the risk of T-cell malignancies following CAR-T cell immunotherapies. Review the key points of this announcement concerning the CGT research community. |
|
|
|
| The Future Of Plasmid DNA Upstream Optimization | Article | AGC Biologics | An optimized upstream manufacturing process is crucial for producing the necessary amount of plasmid DNA required for the growing number of therapeutic and vaccine applications available. |
|
|
|
|
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
